InMusc - Instituto de Salud Musculoesquelética

At InMusc - Instituto de Salud Musculoesquelética, we have just returned from a few days in Milan, where we participated in the kick-off meeting of the incredible MDR-RA Project, a #HorizonEurope-funded initiative dedicated to combating #MultiDrugResistance in rheumatoid arthritis (#RA). Over the next five years, our 23 partners from 12 countries will work together to revolutionise how we understand, diagnose and treat #DifficultToTreat #RA. Ready to go! 🚀

🎙️ We are finally properly kicking off the MDR-RA project! Today, our Scientific Coordinator, Prof. Costantino Pitzalis of Queen Mary University of London and Humanitas Research Hospital officially opened the MDR-RA Kick-off Meeting in Milan, Italy with an inspiring message about the project’s bold vision: “Together, we will revolutionize care for #RheumatoidArthritis (RA) by better understanding and tackling multi-drug resistance.” 🔑 Key messages from his address: 🔹 The ambitious iCare-RA predictive tool developed under the lead of Inmusc with the help of the great minds of the consortium, will integrate clinical, imaging, and molecular data to personalize #RA treatments. 🔹 Patients are at the heart of our mission, ensuring every step is patient-centered and truly effective in bettering the lives of people suffering most from RA. Stay tuned for updates as we embark on this transformative journey and feel free to follow us and spread the word! #MDRRA #HorizonEurope #Rheumatology #InnovationInHealthcare #PatientCare #HADEA EULAR - European Alliance of Associations for Rheumatology #EUprojects #Innovation #PatientAdvocacy

Finally, to close the kick-off, the importance of communication. Here, Loreto Carmona, the WP leader of communications, explains the difference between dissemination, communication, and exploitation.

Inmusc joins the start of a new IHI project to advance imaging in arthritis. European research partners, pharmaceutical companies, small and medium-sized enterprises (SMEs), and patient organisations have joined forces under the Innovative Health Initiative (IHI) public-private partnership to improve the diagnosis, treatment decisions, and monitoring of major rheumatic diseases. The newly launched IHI AutoPiX project will leverage AI to make clinical imaging more interpretable to scientists, clinicians, and patients. Vienna, 9 December 2024 — To enhance imaging biomarkers for patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, the IHI-funded AutoPiX project brings together world-class pharmaceutical and medical technology partners with leading academic institutions. These immune-mediated inflammatory diseases affect millions of people across Europe—approximately 4 million for rheumatoid arthritis, 1.3 million for psoriatic arthritis, and 3 to 5 million for axial spondyloarthritis. They share challenges, including the need for timely diagnosis at non-specialist institutions, early and targeted intervention, and effective monitoring. The AutoPiX consortium aims to address critical unmet medical needs in imaging in rheumatology. These include limited access to specific techniques, such as ultrasound outside reference centres and hospitals, and precision gaps in selecting the most suitable treatments for arthritis. AI-supported imaging biomarkers could enhance precision medicine and early diagnosis and enable accessible narratives for clinicians and patients. In the words of AutoPiX Coordinator Prof. Daniel Aletaha from the Medizinische Universität Wien, “We will bring imaging closer to the practising clinician and the patient, ensuring that it becomes more accessible, interpretable, and clinically relevant for disease management that requires high levels of expertise”. A significant commitment of the project is to enhance the sustainability and efficiency of imaging. “We have an opportunity to minimize the burden associated with imaging and make the interpretation more efficient and objective,” says the consortium Project Lead, Rob Janiczek, PhD, Director of Clinical Science Imaging (Janssen R&D LLC), representative of the Project Leader Janssen Pharmaceutica NV, a Johnson & Johnson company.

The InMusc - Instituto de Salud Musculoesquelética team is back home, thinking about everything we have enjoyed, learned, and shared with the members of the SQUEEZE project. Our batteries are recharged for all the work ahead of us next year. Let's go, team! 

A year has passed since the last general assembly of our project. So many things have happened! In WP8, we're ready to start delineating and cocreating the SQUEEZE care model. Today, we are having the update presentation by Agnes Kocher and, later, a breakout to discuss the processes with Andreas Dam and Jef Van Rompay, among others. Tomorrow, we will involve the whole consortium in a workshop to start thinking about how to make SQUEEZE shine in a care model, led by the InMusc - Instituto de Salud Musculoesquelética, with Estibaliz Loza Santamaria, Teresa Otón Sánchez, and Loreto Carmona, and Kristina Chingov from EULAR, and later a breakout on the stakeholder involvement. So many learnings!!! Go team 🚀!!!

🌍 Today, on the Global Day Against Pain, we stand united with #healthcare professionals, #patients, and advocates worldwide to raise awareness about the urgent need for effective #painmanagement. Pain impacts millions globally, diminishing quality of life and well-being. Understanding pain is the first crucial step towards compassionate #care and effective relief. At SQUEEZE, we are committed to advancing pain management solutions through #research, #education, and #support. We prioritize educational initiatives for both healthcare providers and patients to ensure informed decision-making in pain management strategies. Let’s spread knowledge, foster a community dedicated to improving the lives of those suffering from chronic and acute pain, and advocate for continued advancements in pain research and treatment. How is your organization addressing pain relief? Share your stories and initiatives with us. #GlobalDayAgainstPain #PainManagement #EducationFirst #HealthcareInnovation #PatientCare #ChronicPainAwareness #HorizonEurope #EUfunding #EUproject #SERI #UKRI #HADEA

💊 Here comes the 3️⃣rd issue of our #SQUEEZE newsletter!! 🗞️ Learn about our work, about us, and our #clinicaltrials! 🏁 On a bi-annual basis, we will publish insights into our daily collaboration within our 14 partners #horizoneurope funded project. Follow us to not miss the next issue! Thanks to François Bonnay, PhD, Kristina Chingov, Loreto Carmona and Caroline Dürrschmid for your valuable input to this edition! 🙏🏼 #newsletter #horizoneurope #hadea #EUproject #InnovationInHealthcare #RheumatoidArthritis #RA #Innovation #ClinicalStudy #ClinicalTrial

In recognition of Arthritis Awareness Month and World Arthritis Day #WAD2024 on October 12th, we are proud to highlight our ongoing efforts within the SQUEEZE consortium to improve the lives of individuals living with #rheumatoid #arthritis (RA). RA is a chronic, inflammatory condition affecting millions worldwide. It causes joint pain and stiffness and significantly impacts quality of life. This year’s theme, "Informed Choices, Better Outcomes," perfectly aligns with our project's core objectives. Our research focuses on optimizing and personalizing existing treatments, providing patients with tailored therapeutic options to manage their condition better. We emphasize the importance of patient involvement by including patient research partners in all our work packages, ensuring that their perspectives and experiences shape the direction of our efforts. A key component of our work at Inmusc is the commitment to translating research findings from ongoing clinical trials in other work packages of SQUEEZE and published studies into a practical, real-world care model grounded in shared decision-making, i.e., "informed choices, better choices."

Dear colleagues, rheumatologists, and health professionals taking care of people with #RMDs! 👇 Check this survey by Kaleb Michaud about knowledge, attitudes, and practice (KAP) regarding cannabis funded by the Rheumatology Research Foundation. It does not matter if you have never used cannabis, used cannabis in the past, currently use it, or if cannabis is legal where you reside or practice. Visit https://lnkd.in/dr4SdJcm for more information or questions